-- Presentation to be webcast on www.exelixis.com
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 7, 2017--
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s President and Chief Executive Officer, will provide
an overview of the company at Leerink’s Global Healthcare Conference
taking place February 15-16 in New York, NY. The Exelixis presentation
is scheduled for 9:30 AM EST / 6:30 AM PST on Wednesday, February 15,
The presentation will be webcast live and may be accessed via the Event
Calendar page under Investors & Media at www.exelixis.com.
Please connect to the company’s website at least 15 minutes prior to the
presentation to ensure adequate time for any software download that may
be required to listen to the webcast. A replay will also be available at
the same location for 14 days.
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed
to the discovery, development and promotion of new medicines with the
potential to improve care and outcomes for people with cancer. Since its
founding in 1994, three medicines discovered at Exelixis have progressed
through clinical development to receive regulatory approval. Currently,
Exelixis is focused on advancing cabozantinib, an inhibitor of multiple
tyrosine kinases including MET, AXL and VEGF receptors, which has shown
clinical anti-tumor activity in more than 20 forms of cancer and is the
subject of a broad clinical development program. Two separate
formulations of cabozantinib have received regulatory approval to treat
certain forms of kidney and thyroid cancer and are marketed for those
purposes as CABOMETYX™ tablets (U.S. and EU) and COMETRIQ®
capsules (U.S. and EU), respectively. Another Exelixis-discovered
compound, COTELLIC® (cobimetinib), a selective inhibitor of
MEK, has been approved in major territories including the United States
and European Union, and is being evaluated for further potential
indications by Roche and Genentech (a member of the Roche Group) under a
collaboration with Exelixis. For more information on Exelixis, please
or follow @ExelixisInc on Twitter.
Exelixis, the Exelixis logo, COMETRIQ and COTELLIC are registered
U.S. trademarks, and CABOMETYX is a U.S. trademark.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170207006298/en/
Source: Exelixis, Inc.
Susan Hubbard, 650-837-8194
President, Public Affairs and Investor Relations
For Exelixis, Inc.
Hal Mackins, 415-994-0040